Generative AI is moving from isolated pilots to full-scale deployments, with adoption accelerating in areas like software development and IT service management.
2025 was the year generative AI grew up, shifting from isolated experiments to integrated systems. What also emerged was a clearer picture of how AI will continue to mature in 2026.
The U.S. shift toward most-favored-nation (MFN) drug pricing is forcing pharmaceutical firms to rethink their pricing models and launch strategies in Europe.